Patents by Inventor Paul Nioi

Paul Nioi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLUTE CARRIER FAMILY MEMBER IRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20240141358
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting a solute carrier family member gene, e.g., SLC30A10, or SLC39A8. The invention also relates to methods of using such RNAi agents to inhibit expression of a solute carrier family member gene, e.g., an SLC30A10 gene, or an SLC39A8 gene, and to methods of preventing and treating a solute carrier family member-associated disorder, e.g., a hypermanganesemia.
    Type: Application
    Filed: October 16, 2020
    Publication date: May 2, 2024
    Inventors: Lucas D. Ward, Ho-Chou Tu, James D. McIninch, Paul Nioi
  • NEUROFILAMENT LIGHT CHAIN (NFL) AS A BIOMARKER FOR TRANSTHYRETIN AMYLOIDOSIS POLYNEUROPATHY
    Publication number: 20230024849
    Abstract: The disclosure provides biomarkers for diagnosis and monitoring of transthyretin (TTR) amyloidosis. The disclosure further provides methods for selection of agents for treatment of TTR amyloidosis using the biomarkers. The disclosure further provides kits for practicing the methods provided herein.
    Type: Application
    Filed: February 16, 2022
    Publication date: January 26, 2023
    Inventors: Simina Ticau, Paul Nioi, Gautham Vivek Sridharan, Shira Tsour
  • Methods of treating cardiovascular disease with an anti-ASGR antibody or binding fragments thereof
    Patent number: 11066472
    Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: July 20, 2021
    Assignee: Amgen Inc.
    Inventors: Paul Nioi, Peter Coward, Christopher Murawsky
  • ASGR INHIBITORS
    Publication number: 20210163601
    Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.
    Type: Application
    Filed: August 6, 2020
    Publication date: June 3, 2021
    Inventors: Paul Nioi, Peter Coward, Christopher Murawsky, Derek E. Piper, Fernando Garces, Jun Zhang, Yang Li, Brian Mingtung Chan
  • ASGR INHIBITORS
    Publication number: 20190248902
    Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.
    Type: Application
    Filed: December 21, 2018
    Publication date: August 15, 2019
    Inventors: Paul Nioi, Peter Coward, Christopher Murawsky, Derek E. Piper, Fernando Garces, Jun Zhang, Yang Li, Brian Mingtung Chan
  • Methods of treating cardiovascular disease with an ASGR inhibitor
    Patent number: 10358497
    Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: July 23, 2019
    Assignee: AMGEN INC.
    Inventors: Paul Nioi, Jun Zhang, Yang Li
  • ASGR INHIBITORS
    Publication number: 20170088620
    Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.
    Type: Application
    Filed: September 28, 2016
    Publication date: March 30, 2017
    Inventors: Paul Nioi, Peter Coward, Christopher Murawsky, Derek E. Piper, Fernando Garces, Jun Zhang, Yang Li, Brian Mintung Chang